trial

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

NCTId NCT00694707
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 732 (actual)
Sponsored by Forest Laboratories
Primary completion 2009-08-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
732 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-06-30
Primary completion
2009-08-31
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Cariprazine (Vraylar)Risperidone

Sponsors

Forest LaboratoriesLead Sponsor
Gedeon Richter Ltd.Collaborator

Investigators

1
Suresh Durgam, MDStudy Director

Sites

65 total
Costa Mesa, United StatesLong Beach, United StatesOceanside, United StatesParamount, United StatesRiverside, United StatesWashington D.C., United StatesBradenton, United StatesKissimmee, United StatesLake Charles, United StatesBaltimore, United StatesFlowood, United StatesBridgeton, United States

Linked catalysts

1
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizo — primary completion2009-08-31

Facts & assertions

4 sourced
Enrollment
732
Phase
PHASE2
Primary Completion Date
2009-08-31
Status
COMPLETED
relationships
The graph out of here
drug
Cariprazine (Vraylar)
drug
Risperidone
drug
lead_sponsor
Forest Laboratories
company
collaborator
Gedeon Richter Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Suresh Durgam, MD
person